Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: PaxMedica Inc. PXMD

MissionIRNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Marks Major Milestone in Preparations for NDA Submission, Global Suramin Supply

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, recently completed its three registration/validation batches of PAX-101, an IV formulation of suramin. “This accomplishment marks a significant step toward submitting a New Drug Application (‘NDA’) to … Continue reading

Posted in PaxMedica Inc. PXMD | Leave a comment

PaxMedica Inc. (NASDAQ: PXMD) Shares Corporate Update and Commitment to Advancing Therapies for Neurological Disorders, Prepares for Key Engagements with the FDA

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company specializing in neurological disorder treatments, recently shared corporate updates regarding its continued progress toward establishing suramin as an accepted treatment for Human African Trypanosomiasis (“HAT”). PaxMedica is preparing to submit a New Drug Application … Continue reading

Posted in PaxMedica Inc. PXMD | Leave a comment

PaxMedica Inc. (NASDAQ: PXMD) Seeking to Qualify for Neglected Tropical Disease Priority Review Voucher Program in Wake of Malawi Major Sleeping Sickness Crisis

PaxMedica (NASDAQ: PXMD), a biopharmaceutical firm dedicated to advancing treatments for neurological disorders, recently announced that it has received an urgent plea from the Ministry of Health (“MOH”) of Malawi. The MOH is requesting emergency access to IV suramin to … Continue reading

Posted in PaxMedica Inc. PXMD | Leave a comment

MissionIRNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Dedicated to Ensuring Access to Life-Saving Treatments

PaxMedica (NASDAQ: PXMD), a renowned biopharmaceutical company specializing in treatments for neurological disorders, recently took swift action to address a pressing medical situation unfolding in Malawi, East Africa. “The Ministry of Health (‘MOH’) of Malawi has issued a plea for … Continue reading

Posted in PaxMedica Inc. PXMD | Leave a comment

PaxMedica Inc. (NASDAQ: PXMD) Announces PAX-101 Batch Completion for NDA Application to FDA

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, recently announced that it has completed its three registration/validation batches of PAX-101, an IV formulation of suramin. This accomplishment marks a significant step toward submitting a New … Continue reading

Posted in PaxMedica Inc. PXMD | Leave a comment

“Urgent Action: PaxMedica Inc. (NASDAQ: PXMD) Addresses Medical Crisis in Malawi”

In recent developments, PaxMedica (NASDAQ: PXMD), a renowned biopharmaceutical company specializing in treatments for neurological disorders, has taken swift action to address a pressing medical situation unfolding in Malawi, East Africa. The Ministry of Health (“MOH”) of Malawi has issued … Continue reading

Posted in PaxMedica Inc. PXMD | Leave a comment

MissionIRNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Developing Robust Product Lineup to Address ASD, Associated Neurodevelopmental Conditions

PaxMedica (NASDAQ: PXMD) is a clinical-stage biopharmaceutical company focused on the development of novel anti-purinergic therapies (“APTs”) for the treatment of autism spectrum disorder (“ASD”) and other serious conditions with intractable neurologic symptoms. The company is on a promising path … Continue reading

Posted in PaxMedica Inc. PXMD | Leave a comment

PaxMedica Inc. (NASDAQ: PXMD) Developing Pipeline to Address Unmet Needs in Autism Spectrum Disorder via Suramin Sodium

Researchers used to believe that autism spectrum disorder only affected one in 2,500 children – today, that estimation is closer to one in 36 children. Between 1998 and 2018, research has found more than a 780% increase in the number … Continue reading

Posted in PaxMedica Inc. PXMD | Leave a comment

MissionIRNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) on Promising Path to Meet Medical Needs of ASD Patients

PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company focusing on the development of novel anti-purinergic therapies (“APTs”), is focusing its lead program on autism spectrum disorder (“ASD”), for which there is no approved pharmacologic treatment targeting cause and symptoms. “The current … Continue reading

Posted in PaxMedica Inc. PXMD | Leave a comment

MissionIRNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Shares Vision, Innovations in ASD Treatments in Updated Company Presentation

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced the release of its latest company presentation. The comprehensive overview showcases PaxMedica’s strategic direction, recent advancements in autism spectrum disorder (“ASD”) therapeutics, and its commitment … Continue reading

Posted in PaxMedica Inc. PXMD | Leave a comment